View Future GrowthRBC Bioscience 過去の業績過去 基準チェック /36RBC Bioscienceの収益は年間平均-51.7%の割合で減少していますが、 Life Sciences業界の収益は年間 増加しています。収益は年間6.3% 21.6%割合で 減少しています。 RBC Bioscienceの自己資本利益率は8.8%であり、純利益率は10.7%です。主要情報-51.71%収益成長率-56.08%EPS成長率Life Sciences 業界の成長5.47%収益成長率-21.61%株主資本利益率8.77%ネット・マージン10.72%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Apr 26Full year 2025 earnings released: EPS: NT$1.65 (vs NT$1.51 in FY 2024)Full year 2025 results: EPS: NT$1.65 (up from NT$1.51 in FY 2024). Revenue: NT$219.7m (up 7.0% from FY 2024). Net income: NT$23.5m (up 9.2% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 25Full year 2023 earnings released: EPS: NT$0.50 (vs NT$0.29 in FY 2022)Full year 2023 results: EPS: NT$0.50 (up from NT$0.29 in FY 2022). Revenue: NT$172.5m (flat on FY 2022). Net income: NT$6.43m (up 70% from FY 2022). Profit margin: 3.7% (up from 2.2% in FY 2022).すべての更新を表示Recent updatesReported Earnings • Apr 26Full year 2025 earnings released: EPS: NT$1.65 (vs NT$1.51 in FY 2024)Full year 2025 results: EPS: NT$1.65 (up from NT$1.51 in FY 2024). Revenue: NT$219.7m (up 7.0% from FY 2024). Net income: NT$23.5m (up 9.2% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Buy Or Sell Opportunity • Apr 15Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 9.1% to NT$17.90. The fair value is estimated to be NT$14.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.お知らせ • Apr 01RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2026RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2026. Location: 15 floor no,15, ch`iao huo rd., jhonghe district, new taipei city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.8% operating cash flow to total debt). Earnings have declined by 63% per year over the past 5 years. Market cap is less than US$10m (NT$218.6m market cap, or US$6.97m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.New Risk • Jan 14New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.8% operating cash flow to total debt). Earnings have declined by 63% per year over the past 5 years. Market cap is less than US$10m (NT$212.8m market cap, or US$6.72m). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Buy Or Sell Opportunity • Dec 16Now 21% overvaluedOver the last 90 days, the stock has fallen 7.6% to NT$17.00. The fair value is estimated to be NT$14.10, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.Buy Or Sell Opportunity • Nov 26Now 21% overvaluedOver the last 90 days, the stock has fallen 5.7% to NT$17.30. The fair value is estimated to be NT$14.32, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.Buy Or Sell Opportunity • Nov 11Now 21% overvaluedOver the last 90 days, the stock has fallen 2.0% to NT$17.55. The fair value is estimated to be NT$14.53, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.Upcoming Dividend • Sep 25Upcoming dividend of NT$0.30 per shareEligible shareholders must have bought the stock before 02 October 2025. Payment date: 31 October 2025. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (0.7%).お知らせ • Mar 31RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2025RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2025. Location: 15 floor no,15, ch`iao huo rd., jhonghe district, new taipei city TaiwanNew Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$260.2m market cap, or US$7.90m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.New Risk • Dec 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$254.3m market cap, or US$7.75m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.1% average weekly change).New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$267.3m market cap, or US$8.32m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.4% average weekly change).Valuation Update With 7 Day Price Move • Oct 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$20.30, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 29x in the Life Sciences industry in Asia. Total loss to shareholders of 44% over the past three years.Valuation Update With 7 Day Price Move • Oct 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$22.70, the stock trades at a trailing P/E ratio of 17.1x. Average trailing P/E is 30x in the Life Sciences industry in Asia. Total returns to shareholders of 59% over the past year.Upcoming Dividend • Sep 12Upcoming dividend of NT$0.56 per shareEligible shareholders must have bought the stock before 19 September 2024. Payment date: 18 October 2024. Payout ratio is on the higher end at 75%, however this is supported by cash flows. Trailing yield: 5.6%. Within top quartile of Taiwanese dividend payers (4.5%). Higher than average of industry peers (1.2%).Upcoming Dividend • Jul 29Upcoming dividend of NT$0.44 per shareEligible shareholders must have bought the stock before 05 August 2024. Payment date: 30 August 2024. Payout ratio is on the higher end at 89%, and the cash payout ratio is above 100%. Trailing yield: 2.4%. Lower than top quartile of Taiwanese dividend payers (4.3%). Higher than average of industry peers (1.3%).Reported Earnings • Apr 25Full year 2023 earnings released: EPS: NT$0.50 (vs NT$0.29 in FY 2022)Full year 2023 results: EPS: NT$0.50 (up from NT$0.29 in FY 2022). Revenue: NT$172.5m (flat on FY 2022). Net income: NT$6.43m (up 70% from FY 2022). Profit margin: 3.7% (up from 2.2% in FY 2022).お知らせ • Apr 12RBC Bioscience Corporation, Annual General Meeting, Jun 27, 2024RBC Bioscience Corporation, Annual General Meeting, Jun 27, 2024.New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.3x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (NT$209.6m market cap, or US$6.63m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change).Buy Or Sell Opportunity • Feb 20Now 23% undervaluedOver the last 90 days, the stock has risen 5.3% to NT$15.90. The fair value is estimated to be NT$20.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Jan 22Now 20% undervaluedOver the last 90 days, the stock has risen 4.8% to NT$15.25. The fair value is estimated to be NT$19.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.Buying Opportunity • Jan 16Now 21% undervaluedOver the last 90 days, the stock is up 3.8%. The fair value is estimated to be NT$19.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.Buying Opportunity • Nov 29Now 20% undervaluedOver the last 90 days, the stock is up 3.7%. The fair value is estimated to be NT$19.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.Upcoming Dividend • Jul 06Upcoming dividend of NT$1.12 per share at 6.2% yieldEligible shareholders must have bought the stock before 13 July 2023. Payment date: 11 August 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 6.2%. Within top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (1.0%).Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$21.25, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 29x in the Life Sciences industry in Asia. Total loss to shareholders of 40% over the past year.Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 26%After last week's 26% share price gain to NT$17.75, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 31x in the Life Sciences industry in Asia. Total loss to shareholders of 49% over the past year.Valuation Update With 7 Day Price Move • Dec 27Investor sentiment improved over the past weekAfter last week's 20% share price gain to NT$17.70, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 30x in the Life Sciences industry in Asia. Total loss to shareholders of 43% over the past year.Valuation Update With 7 Day Price Move • Apr 18Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$47.15, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 35x in the Life Sciences industry in Asia.収支内訳RBC Bioscience の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史TPEX:6848 収益、費用、利益 ( )TWD Millions日付収益収益G+A経費研究開発費31 Dec 2522024491730 Sep 2521122511430 Jun 2520220521231 Mar 2520421531131 Dec 2420522531030 Sep 2420019511030 Jun 2419517491031 Mar 2418412481031 Dec 231726481130 Sep 231662471230 Jun 23161-2471431 Mar 231671481531 Dec 221744501630 Sep 221929511530 Jun 2221013521431 Mar 2223021521531 Dec 2125129521630 Sep 2137474662230 Jun 21497120812731 Mar 21536131862531 Dec 20575142902231 Dec 191621439931 Dec 1812614358質の高い収益: 6848は 高品質の収益 を持っています。利益率の向上: 6848の現在の純利益率 (10.7%)は、昨年(10.5%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 6848の収益は過去 5 年間で年間51.7%減少しました。成長の加速: 6848の過去 1 年間の収益成長率 ( 9.2% ) は、5 年間の平均 ( 年間-51.7%を上回っています。収益対業界: 6848の過去 1 年間の収益成長率 ( 9.2% ) Life Sciences業界19.1%を上回りませんでした。株主資本利益率高いROE: 6848の 自己資本利益率 ( 8.8% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 21:02終値2026/06/10 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋RBC Bioscience Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 26Full year 2025 earnings released: EPS: NT$1.65 (vs NT$1.51 in FY 2024)Full year 2025 results: EPS: NT$1.65 (up from NT$1.51 in FY 2024). Revenue: NT$219.7m (up 7.0% from FY 2024). Net income: NT$23.5m (up 9.2% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 25Full year 2023 earnings released: EPS: NT$0.50 (vs NT$0.29 in FY 2022)Full year 2023 results: EPS: NT$0.50 (up from NT$0.29 in FY 2022). Revenue: NT$172.5m (flat on FY 2022). Net income: NT$6.43m (up 70% from FY 2022). Profit margin: 3.7% (up from 2.2% in FY 2022).
Reported Earnings • Apr 26Full year 2025 earnings released: EPS: NT$1.65 (vs NT$1.51 in FY 2024)Full year 2025 results: EPS: NT$1.65 (up from NT$1.51 in FY 2024). Revenue: NT$219.7m (up 7.0% from FY 2024). Net income: NT$23.5m (up 9.2% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Buy Or Sell Opportunity • Apr 15Now 25% overvalued after recent price riseOver the last 90 days, the stock has risen 9.1% to NT$17.90. The fair value is estimated to be NT$14.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.
お知らせ • Apr 01RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2026RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2026. Location: 15 floor no,15, ch`iao huo rd., jhonghe district, new taipei city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.8% operating cash flow to total debt). Earnings have declined by 63% per year over the past 5 years. Market cap is less than US$10m (NT$218.6m market cap, or US$6.97m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
New Risk • Jan 14New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.8% operating cash flow to total debt). Earnings have declined by 63% per year over the past 5 years. Market cap is less than US$10m (NT$212.8m market cap, or US$6.72m). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Buy Or Sell Opportunity • Dec 16Now 21% overvaluedOver the last 90 days, the stock has fallen 7.6% to NT$17.00. The fair value is estimated to be NT$14.10, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.
Buy Or Sell Opportunity • Nov 26Now 21% overvaluedOver the last 90 days, the stock has fallen 5.7% to NT$17.30. The fair value is estimated to be NT$14.32, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.
Buy Or Sell Opportunity • Nov 11Now 21% overvaluedOver the last 90 days, the stock has fallen 2.0% to NT$17.55. The fair value is estimated to be NT$14.53, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 53%.
Upcoming Dividend • Sep 25Upcoming dividend of NT$0.30 per shareEligible shareholders must have bought the stock before 02 October 2025. Payment date: 31 October 2025. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (0.7%).
お知らせ • Mar 31RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2025RBC Bioscience Corporation, Annual General Meeting, Jun 26, 2025. Location: 15 floor no,15, ch`iao huo rd., jhonghe district, new taipei city Taiwan
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$260.2m market cap, or US$7.90m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
New Risk • Dec 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$254.3m market cap, or US$7.75m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.1% average weekly change).
New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.7% operating cash flow to total debt). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (NT$267.3m market cap, or US$8.32m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.4% average weekly change).
Valuation Update With 7 Day Price Move • Oct 23Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$20.30, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 29x in the Life Sciences industry in Asia. Total loss to shareholders of 44% over the past three years.
Valuation Update With 7 Day Price Move • Oct 08Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$22.70, the stock trades at a trailing P/E ratio of 17.1x. Average trailing P/E is 30x in the Life Sciences industry in Asia. Total returns to shareholders of 59% over the past year.
Upcoming Dividend • Sep 12Upcoming dividend of NT$0.56 per shareEligible shareholders must have bought the stock before 19 September 2024. Payment date: 18 October 2024. Payout ratio is on the higher end at 75%, however this is supported by cash flows. Trailing yield: 5.6%. Within top quartile of Taiwanese dividend payers (4.5%). Higher than average of industry peers (1.2%).
Upcoming Dividend • Jul 29Upcoming dividend of NT$0.44 per shareEligible shareholders must have bought the stock before 05 August 2024. Payment date: 30 August 2024. Payout ratio is on the higher end at 89%, and the cash payout ratio is above 100%. Trailing yield: 2.4%. Lower than top quartile of Taiwanese dividend payers (4.3%). Higher than average of industry peers (1.3%).
Reported Earnings • Apr 25Full year 2023 earnings released: EPS: NT$0.50 (vs NT$0.29 in FY 2022)Full year 2023 results: EPS: NT$0.50 (up from NT$0.29 in FY 2022). Revenue: NT$172.5m (flat on FY 2022). Net income: NT$6.43m (up 70% from FY 2022). Profit margin: 3.7% (up from 2.2% in FY 2022).
お知らせ • Apr 12RBC Bioscience Corporation, Annual General Meeting, Jun 27, 2024RBC Bioscience Corporation, Annual General Meeting, Jun 27, 2024.
New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.3x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (NT$209.6m market cap, or US$6.63m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (6.6% average weekly change).
Buy Or Sell Opportunity • Feb 20Now 23% undervaluedOver the last 90 days, the stock has risen 5.3% to NT$15.90. The fair value is estimated to be NT$20.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Jan 22Now 20% undervaluedOver the last 90 days, the stock has risen 4.8% to NT$15.25. The fair value is estimated to be NT$19.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.
Buying Opportunity • Jan 16Now 21% undervaluedOver the last 90 days, the stock is up 3.8%. The fair value is estimated to be NT$19.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.
Buying Opportunity • Nov 29Now 20% undervaluedOver the last 90 days, the stock is up 3.7%. The fair value is estimated to be NT$19.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 23% over the last year. Meanwhile, the company became loss making.
Upcoming Dividend • Jul 06Upcoming dividend of NT$1.12 per share at 6.2% yieldEligible shareholders must have bought the stock before 13 July 2023. Payment date: 11 August 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 6.2%. Within top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (1.0%).
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$21.25, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 29x in the Life Sciences industry in Asia. Total loss to shareholders of 40% over the past year.
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment improves as stock rises 26%After last week's 26% share price gain to NT$17.75, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 31x in the Life Sciences industry in Asia. Total loss to shareholders of 49% over the past year.
Valuation Update With 7 Day Price Move • Dec 27Investor sentiment improved over the past weekAfter last week's 20% share price gain to NT$17.70, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 30x in the Life Sciences industry in Asia. Total loss to shareholders of 43% over the past year.
Valuation Update With 7 Day Price Move • Apr 18Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$47.15, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 35x in the Life Sciences industry in Asia.